Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4905417 in non-ST-elevation myocardial infarction patients undergoing PCI
NL-OMON35644Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of inclacumab in Non-ST-segment elevation myocardial infarction (NSTEMI) (3 arms), sponsored by Roche. Primary endpoint: Primary efficacy endpoint. Started Mar 2012; status: active, not recruiting.
02
Drugs
inclacumab
03
Conditions
Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NL-OMON35644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35644.